Epigenetics and Disease

Pharmaceutical Opportunities

  • Susan M. Gasser
  • En Li

Part of the Progress in Drug Research book series (PDR, volume 67)

Table of contents

  1. Front Matter
    Pages i-x
  2. Phillippa C. Taberlay, Peter A. Jones
    Pages 1-23
  3. Yoon Jung Park, Rainer Claus, Dieter Weichenhan, Christoph Plass
    Pages 25-49
  4. Primo Schär, Olivier Fritsch
    Pages 51-68
  5. Siavash K. Kurdistani
    Pages 91-106
  6. Anne Schaefer, Alexander Tarakhovsky, Paul Greengard
    Pages 125-146
  7. Shigeki Iwase, Yang Shi
    Pages 147-173
  8. Peter W. Atadja
    Pages 175-195
  9. Antoine H. F. M. Peters, Juerg Schwaller
    Pages 197-219
  10. Witold Filipowicz, Helge Großhans
    Pages 221-238
  11. Yun Shen Chan, Lin Yang, Huck-Hui Ng
    Pages 239-252
  12. Xu Yuan, Wenlin Li, Sheng Ding
    Pages 253-266
  13. Back Matter
    Pages 267-270

About this book

Introduction

Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This volume explores the scientific background for clinical applications of epigenetically active drugs. Included are descriptions of epigenetic controls over gene expression, the post-transcriptional silencing of genes by RNA interference (RNAi) and microRNAs, as well as new findings from stem cell research which are relevant to pharmacological applications.

Keywords

DNA methylation cancer neuronal disorders stem cells therapy

Editors and affiliations

  • Susan M. Gasser
    • 1
  • En Li
    • 2
  1. 1.for Biomedical Research, Part of the Novartis Research FoundationFriedrich Miescher InstituteBaselSwitzerland
  2. 2.BioMedical Research Co., Ltd.China Novartis Institutes forShanghaiChina, People's Republic

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-7643-8989-5
  • Copyright Information Springer Basel AG 2011
  • Publisher Name Springer, Basel
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-7643-8988-8
  • Online ISBN 978-3-7643-8989-5
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma